<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.virologyj.com/feeds/latestarticles/journal?quantity=&amp;format=rss&amp;version=">
        <title>Virology Journal - Latest Articles</title>
        <link>http://www.virologyj.com</link>
        <description>The latest research articles published by Virology Journal</description>
        <dc:date>2009-07-03T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.virologyj.com/content/6/1/92" />
                                <rdf:li rdf:resource="http://www.virologyj.com/content/6/1/91" />
                                <rdf:li rdf:resource="http://www.virologyj.com/content/6/1/90" />
                                <rdf:li rdf:resource="http://www.virologyj.com/content/6/1/89" />
                                <rdf:li rdf:resource="http://www.virologyj.com/content/6/1/88" />
                                <rdf:li rdf:resource="http://www.virologyj.com/content/6/1/87" />
                                <rdf:li rdf:resource="http://www.virologyj.com/content/6/1/86" />
                                <rdf:li rdf:resource="http://www.virologyj.com/content/6/1/85" />
                                <rdf:li rdf:resource="http://www.virologyj.com/content/6/1/84" />
                                <rdf:li rdf:resource="http://www.virologyj.com/content/6/1/83" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.virologyj.com/content/6/1/92">
        <title>Characterization of subcellular localization of duck enteritis virus UL51 protein</title>
        <description>Background:
Knowledge of the subcellular localization of a protein can provide useful insights about its function. While the subcellular localization of many alphaherpesvirus UL51 proteins has been well characterized, little is known about where duck enteritis virus (DEV) UL51 protein (pUL51) is targeted to. Thus, in this study, we investigated the subcellular localization and distribution of DEV pUL51 by computer aided analysis, as well as indirect immunofluorescence (IIF) and transmission immunoelectron microscopy (TIEM) approaches in DEV-infected cells. Results: The DEV UL51 gene product was identified as an approximate 34 kDa protein in DEV-infected cells analyzed by western blotting. Computer aided analysis suggested that DEV pUL51 is not targeted to the mitochondrial, extra-cellular or nucleus, but be targeted to the cytoplasmic in host cells, more specifically, palmitoylation of the pUL51 through the N-terminal cysteine at position 9 makes membrane association and Golgi localization possible. Using IIF analysis, we found that DEV pUL51 was first detected in a juxtanuclear region of DEV-infected cells at 9 h postinfection (p.i.), and then was detected widely distributed in the cytoplasm and especially was stronger in the juxtanuclear region from 12 to 60 h p.i. TIEM analysis revealed that DEV pUL51 was mainly associated with cytoplasmic virions and also with some membranous structure near the pUL51-specific immuno-labeling intracellular virion in the cytoplasmic vesicles; moreover, the pUL51 efficiently accumulated in the Golgi apparatus at first, and then was sent to the plasma membrane from the Golgi by some unknown mechanism.
Conclusions:
In this work, we described the basic characteristics of pUL51 subcellular localization and distribution for the first time. From these results, we concluded that palmitoylation at the N-terminal cysteine, which is conserved in all alphaherpesvirus UL51 homologs, is required for its membrane association and Golgi localization, and the pUL51 mainly localized to the juxtanuclear region of DEV-infected cells, as well seemed to be incorporated into mature virions as a component of the tegument. The research will provide useful clues for DEV pUL51 functional analysis, and will be usefull for further understanding the localization properties of alphaherpesvirus UL51 homologs.</description>
        <link>http://www.virologyj.com/content/6/1/92</link>
                <dc:creator>Shen Chanjuan</dc:creator>
                <dc:creator>Guo Yufei</dc:creator>
                <dc:creator>Cheng Anchun</dc:creator>
                <dc:creator>Wang Mingshu</dc:creator>
                <dc:creator>Zhou Yi</dc:creator>
                <dc:creator>Lin Dan</dc:creator>
                <dc:creator>Xin Hongyi</dc:creator>
                <dc:creator>Zhang Na</dc:creator>
                <dc:source>Virology Journal 2009, 6:92</dc:source>
        <dc:date>2009-07-03T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1743-422X-6-92</dc:identifier>
        <prism:publicationName>Virology Journal</prism:publicationName>
        <prism:issn>1743-422X</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>92</prism:startingPage>
        <prism:publicationDate>2009-07-03T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.virologyj.com/content/6/1/91">
        <title>Analysis of host- and strain-dependent cell death responses during infectious salmon anemia virus infection in vitro </title>
        <description>Background:
Infectious salmon anemia virus (ISAV) is an aquatic orthomyxovirus and the causative agent of infectious salmon anemia (ISA), a disease of great importance in the Atlantic salmon farming industry. In vitro, ISAV infection causes cytophatic effect (CPE) in cell lines from Atlantic salmon, leading to rounding and finally detachment of the cells from the substratum. In this study, we investigated the mode of cell death during in vitro ISAV infection in different Atlantic salmon cell lines, using four ISAV strains causing different mortality in vivo.
Results:
The results show that caspase 3/7 activity increased during the course of infection in ASK and SHK-1 cells, infected cells showed increased surface expression of phosphatidylserine and increased PI uptake, compared to mock infected cells; and morphological alterations of the mitochondria were observed. Expression analysis of immune relevant genes revealed that the most pathogenic isolate induced lowest levels of stress response genes.
Conclusions:
Results from this study indicate that there are differences between cell lines commonly used for in vitro ISAV studies, and that the differences seen between isolates in vivo, are less prominent in vitro.</description>
        <link>http://www.virologyj.com/content/6/1/91</link>
                <dc:creator>Berit Schiotz</dc:creator>
                <dc:creator>Espen Baekkevold</dc:creator>
                <dc:creator>Lene Poulsen</dc:creator>
                <dc:creator>Siri Mjaaland</dc:creator>
                <dc:creator>Tor Gjoen</dc:creator>
                <dc:source>Virology Journal 2009, 6:91</dc:source>
        <dc:date>2009-07-01T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1743-422X-6-91</dc:identifier>
        <prism:publicationName>Virology Journal</prism:publicationName>
        <prism:issn>1743-422X</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>91</prism:startingPage>
        <prism:publicationDate>2009-07-01T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.virologyj.com/content/6/1/90">
        <title>Development and Validation of a HPV-32 Specific PCR Assay</title>
        <description>Background:
Human Papillomavirus-32 (HPV-32) has traditionally been associated with focal-epithelial-hyperplasia (FEH). It is also present in 58% of oral warts of HIV-positive individuals whose prevalence is increasing.  Current methods for the detection of HPV-32 are labor-intensive and insensitive so the goal of this work was to develop a highly sensitive and easy to use specific polymerase chain reaction (PCR) assay.Material and Methods: An HPV-32 L1 specific PCR assay was developed and optimized.  The sensitivity and specificity was compared to previous assays utilized for detection (PGMY and MY09/11 PCR with dot blot hybridization) using cloned HPV-32 L1, the closely related HPV-42 L1 as well as clinical samples (oral swabs and fluids from 89 HIV-positive subjects).
Results:
The HPV-32 specific PCR assay showed improved sensitivity to 5 copies of HPV-32 as compared to the PGMY PCR, MY09/11 PCR and dot blot which had a limit of detection of approximately 3,000 copies.  Using the HPV-32 dot blot hybridization assay as the gold standard, the HPV-32 specific PCR assay has a sensitivity of 95.8% and 88.9% by sample and subject, respectively, and specificity was 87.8% and 58.8% by sample and subject, respectively.  The low sensitivity is due to the HPV-32 specific PCR assays ability to detect more HPV-32 positive samples and may be the new gold standard.
Conclusions:
Due to the ease, sensitivity, and specificity the HPV-32 specific PCR assay is superior to previous assays and is ideal for detection of HPV-32 in large cohorts.  This assay provides an excellent tool to study the natural history of HPV-32 infection and the development of oral warts.</description>
        <link>http://www.virologyj.com/content/6/1/90</link>
                <dc:creator>Nicholas Herrel</dc:creator>
                <dc:creator>Nadia Johnson</dc:creator>
                <dc:creator>Jennifer Cameron</dc:creator>
                <dc:creator>Janet Leigh</dc:creator>
                <dc:creator>Michael Hagensee</dc:creator>
                <dc:source>Virology Journal 2009, 6:90</dc:source>
        <dc:date>2009-06-27T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1743-422X-6-90</dc:identifier>
        <prism:publicationName>Virology Journal</prism:publicationName>
        <prism:issn>1743-422X</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>90</prism:startingPage>
        <prism:publicationDate>2009-06-27T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.virologyj.com/content/6/1/89">
        <title>Respiratory viral infections detected by multiplex PCR among pediatric patients with lower respiratory tract infections seen at an urban hospital in Delhi from 2005 to 2007</title>
        <description>Background:
Acute lower respiratory tract infections (ALRI) are the major cause of morbidity and mortality in young children worldwide. Information on viral etiology in ALRI from India is limited. The aim of the present study was to develop a simple, sensitive, specific and cost effective multiplex PCR (mPCR) assay without post PCR hybridization or nested PCR steps for the detection of respiratory syncytial virus (RSV), influenza viruses, parainfluenza viruses (PIV1-3) and human metapneumovirus (hMPV). Nasopharyngeal aspirates (NPAs) were collected from children with ALRI [less than or equal to]5 years of age. The sensitivity and specificity of mPCR was compared to virus isolation by centrifugation enhanced culture (CEC) followed by indirect immunofluorescence (IIF).
Results:
From April 2005-March 2007, 301 NPAs were collected from children attending the outpatient department or admitted to the ward of All India Institute of Medical Sciences hospital at New Delhi, India. Multiplex PCR detected respiratory viruses in 106 (35.2%) of 301 samples with 130 viruses of which RSV was detected in 61, PIV3 in 22, PIV2 in 17, hMPV in 11, PIV1 in 10 and influenza A in 9 children. CEC-IIF detected 79 viruses only. The sensitivity of mPCR was 0.1TCID50 for RSV and influenza A and 1TCID50 for hMPV, PIV1, PIV2, PIV3 and Influenza B. Mixed infections were detected in 18.8% of the children with viral infections, none detected by CEC-IIF. Bronchiolitis was significantly associated with both total viral infections and RSV infection (p&lt;0.05). History of ARI in family predisposed children to acquire viral infection (p&gt;0.05).
Conclusions:
Multiplex PCR offers a rapid, sensitive and reasonably priced diagnostic method for common respiratory viruses.</description>
        <link>http://www.virologyj.com/content/6/1/89</link>
                <dc:creator>Preeti Bharaj</dc:creator>
                <dc:creator>Wayne Sullender</dc:creator>
                <dc:creator>Sushil Kabra</dc:creator>
                <dc:creator>Kalaivani Mani</dc:creator>
                <dc:creator>John Cherain</dc:creator>
                <dc:creator>Vikas Tyagi</dc:creator>
                <dc:creator>Harendra Chahar</dc:creator>
                <dc:creator>Samander Kaushik</dc:creator>
                <dc:creator>Lalit Dar</dc:creator>
                <dc:creator>Shobha Broor</dc:creator>
                <dc:source>Virology Journal 2009, 6:89</dc:source>
        <dc:date>2009-06-26T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1743-422X-6-89</dc:identifier>
        <prism:publicationName>Virology Journal</prism:publicationName>
        <prism:issn>1743-422X</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>89</prism:startingPage>
        <prism:publicationDate>2009-06-26T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.virologyj.com/content/6/1/88">
        <title>Infectious salmon anaemia virus (ISAV) isolated from the ISA disease outbreaks in Chile diverged from ISAV isolates from Norway around 1996 and was disseminated around 2005, based on surface glycoprotein gene sequences</title>
        <description>Background:
Infectious salmon anaemia (ISA) virus (ISAV) is a pathogen of marine-farmed Atlantic salmon (Salmo salar); a disease first diagnosed in Norway in 1984. For over 25 years ISAV has caused major disease outbreaks in the Northern hemisphere, and remains an emerging fish pathogen because of the asymptomatic infections in marine wild fish and the potential for emergence of new epidemic strains. ISAV belongs to the family Orthomyxoviridae, together with influenza viruses but is sufficiently different to be assigned to its own genus, Isavirus. The Isavirus genome consists of eight single-stranded RNA species, and the virions have two surface glycoproteins; fusion (F) protein encoded on segment 5 and haemagglutinin-esterase (HE) protein encoded on segment 6. However, comparision between different ISAV isolates is complicated because there is presently no universally accepted nomenclature system for designation of genetic relatedness between ISAV isolates. The first outbreak of ISA in marine-farmed Atlantic salmon in the Southern hemisphere occurred in Chile starting in June 2007. In order to describe the molecular characteristics of the virus so as to understand its origins, how ISAV isolates are maintained and spread, and their virulence characteristics, we conducted a study where the viral sequences were directly amplified, cloned and sequenced from tissue samples collected from several ISA-affected fish on the different fish farms with confirmed or suspected ISA outbreaks in Chile. This paper describes the genetic characterization of a large number of ISAV strains associated with extensive outbreaks in Chile starting in June 2007, and their phylogenetic relationships with selected European and North American isolates that are representative of the genetic diversity of ISAV.
Results:
RT-PCR for ISAV F and HE glycoprotein genes was performed directly on tissue samples collected from ISA-affected fish on different farms among 14 fish companies in Chile during the ISA outbreaks that started in June 2007. The genes of the F and HE glycoproteins were cloned and sequenced for 51 and 78 new isolates, respectively. An extensive comparative analysis of ISAV F and HE sequence data, including reference isolates sampled from Norway, Faroe Islands, Scotland, USA, and Canada was performed. Based on phylogenetic analysis of concatenated ISAV F and HE genes of 103 individual isolates, the isolates from the ISA outbreaks in Chile grouped in their own cluster of 7 distinct strains within Genotype I (European genotype) of ISAV, with the closest relatedness to Norwegian ISAVs isolated in 1997. The phylogenetic software program, BACKTRACK, estimated the Chile isolates diverged from Norway isolates about 1996 and, therefore, had been present in Chile for some time before the recent outbreaks. Analysis of the deduced F protein sequence showed 43 of 51 Chile isolates with an 11-amino acid insert between 265N and 266Q, with 100% sequence identity with Genotype I ISAV RNA segment 2. Twenty four different HE-HPRs, including HPR0, were detected, with HPR7b making up 79.7%. This is considered a manifestation of ISAV quasispecies HE protein sequence diversity.
Conclusions:
Taken together, these findings suggest that the ISA outbreaks were caused by virus that was already present in Chile that mutated to new strains. This is the first comprehensive report tracing ISAV from Europe to South America.</description>
        <link>http://www.virologyj.com/content/6/1/88</link>
                <dc:creator>Frederick Kibenge</dc:creator>
                <dc:creator>Marcos Godoy</dc:creator>
                <dc:creator>Yingwei Wang</dc:creator>
                <dc:creator>Molly Kibenge</dc:creator>
                <dc:creator>Valentina Gherardelli</dc:creator>
                <dc:creator>Soledad Mansilla</dc:creator>
                <dc:creator>Angelica Lisperger</dc:creator>
                <dc:creator>Miguel Jarpa</dc:creator>
                <dc:creator>Geraldine Larroquete</dc:creator>
                <dc:creator>Fernando Avendano</dc:creator>
                <dc:creator>Marcela Lara</dc:creator>
                <dc:creator>Alicia Gallardo</dc:creator>
                <dc:source>Virology Journal 2009, 6:88</dc:source>
        <dc:date>2009-06-26T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1743-422X-6-88</dc:identifier>
        <prism:publicationName>Virology Journal</prism:publicationName>
        <prism:issn>1743-422X</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>88</prism:startingPage>
        <prism:publicationDate>2009-06-26T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.virologyj.com/content/6/1/87">
        <title>Oral vaccination with a recombinant Salmonella vaccine vector provokes systemic HIV-1 subtype C Gag-specific CD4+ Th1 and Th2 cell immune responses in mice</title>
        <description>Background:
Recombinant Salmonella vaccine vectors may potentially be used to induce specific CD4+ T cell responses against foreign viral antigens. Such immune responses are required features of vaccines against pathogens such as human immunodeficiency virus type 1 (HIV-1). The aim of this study was to investigate the induction of systemic HIV-1-specific CD4+ T helper (Th) responses in mice after oral immunization with a live attenuated Salmonella vaccine vector that expressed HIV-1 subtype C Gag. Groups of BALB/c mice were vaccinated orally three times (4 weeks apart) with this recombinant Salmonella. At sacrifice, 28 days after the last immunization, systemic CD4+ Th1 and Th2 cytokine responses were evaluated by enzyme-linked immunospot assay and cytometric bead array. HIV-1 Gag-specific IgG1 and IgG2a humoral responses in the serum were determined by enzyme-linked immunosorbent assay.
Results:
Mice vaccinated with the recombinant Salmonella elicited both HIV-1-specific Th1 (interferon-gamma (IFN-g) and tumour necrosis factor-alpha (TNF-a)) and Th2 (interleukin-4 (IL-4) and interleukin-5 (IL-5)) cytokine responses. The vaccine induced 70 (IFN-g) spot-forming units (SFUs)/10e6 splenocytes and 238 IL-4 SFUs/10e6 splenocytes. Splenocytes from vaccinated mice also produced high levels of Th1 and Th2 cytokines upon stimulation with a Gag CD4 peptide. The levels of IFN-g, TNF-a, IL-4 and IL-5 were 7.5-, 29.1-, 26.2- and 89.3-fold above the background, respectively. Both HIV-1 Gag-specific IgG1 and IgG2a antibodies were detected in the sera of vaccinated mice.
Conclusions:
The study highlights the potential of orally-delivered attenuated Salmonella as mucosal vaccine vectors for HIV-1 Subtype C Gag to induce Gag-specific CD4+ Th1 and Th2 cellular immune responses and antibodies which may be important characteristics required for protection against HIV-1 infection.</description>
        <link>http://www.virologyj.com/content/6/1/87</link>
                <dc:creator>Nyasha Chin'ombe</dc:creator>
                <dc:creator>William Bourn</dc:creator>
                <dc:creator>Anna-Lise Williamson</dc:creator>
                <dc:creator>Enid Shephard</dc:creator>
                <dc:source>Virology Journal 2009, 6:87</dc:source>
        <dc:date>2009-06-25T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1743-422X-6-87</dc:identifier>
        <prism:publicationName>Virology Journal</prism:publicationName>
        <prism:issn>1743-422X</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>87</prism:startingPage>
        <prism:publicationDate>2009-06-25T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.virologyj.com/content/6/1/86">
        <title>Klassevirus 1, a previously undescribed member of the family Picornaviridae, is globally widespread</title>
        <description>Background:
Diarrhea is the third leading infectious cause of death worldwide and is estimated to be responsible for approximately 2 million deaths a year.  While many infectious causes of diarrhea have been established, approximately 40% of all diarrhea cases are of unknown etiology.  In an effort to identify novel viruses that may be causal agents of diarrhea, we used high throughput mass sequencing to analyze stool samples collected from patients with acute diarrhea.
Results:
Sequences with limited similarity to known picornaviruses were detected in a stool sample collected in Australia from a child with acute diarrhea.  Using a combination of mass sequencing, RT-PCR, 5&apos; RACE and 3&apos; RACE, a 6383 bp fragment of the viral genome was sequenced.  Phylogenetic analysis demonstrated that this virus was highly divergent from, but most closely related to, members of the genus Kobuvirus.  We have tentatively named this novel virus klassevirus 1.  We also detected klassevirus 1 by RT-PCR in a diarrhea specimen collected from a patient in St. Louis, United States as well as in untreated sewage collected in Barcelona, Spain.
Conclusions:
Klassevirus 1 is a previously undescribed picornavirus that is globally widespread and present on at least three continents.  Further investigations to determine whether klassevirus 1 is a human pathogen are needed.</description>
        <link>http://www.virologyj.com/content/6/1/86</link>
                <dc:creator>Lori Holtz</dc:creator>
                <dc:creator>Stacy Finkbeiner</dc:creator>
                <dc:creator>Guoyan Zhao</dc:creator>
                <dc:creator>Carl Kirkwood</dc:creator>
                <dc:creator>Rosina Girones</dc:creator>
                <dc:creator>James Pipas</dc:creator>
                <dc:creator>David Wang</dc:creator>
                <dc:source>Virology Journal 2009, 6:86</dc:source>
        <dc:date>2009-06-24T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1743-422X-6-86</dc:identifier>
        <prism:publicationName>Virology Journal</prism:publicationName>
        <prism:issn>1743-422X</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>86</prism:startingPage>
        <prism:publicationDate>2009-06-24T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.virologyj.com/content/6/1/85">
        <title>Review of &quot;Bioinformatics for vaccinology&quot; edited by Darren R. Flower</title>
        <description>Book review of &quot;Bioinformatics for vaccinology&quot; edited by Darren R. Flower.</description>
        <link>http://www.virologyj.com/content/6/1/85</link>
                <dc:creator>Dae-Won Kim</dc:creator>
                <dc:creator>Hong-Seog Park</dc:creator>
                <dc:source>Virology Journal 2009, 6:85</dc:source>
        <dc:date>2009-06-24T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1743-422X-6-85</dc:identifier>
        <prism:publicationName>Virology Journal</prism:publicationName>
        <prism:issn>1743-422X</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>85</prism:startingPage>
        <prism:publicationDate>2009-06-24T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.virologyj.com/content/6/1/84">
        <title>Hepatitis C virus core, NS3, NS4B and NS5A are the major immunogenic proteins in humoral immunity in chronic HCV infection</title>
        <description>Background:
The viral genome of hepatitis C virus constitutes a 9.6-kb single-stranded positive-sense RNA which encodes altogether 11 viral proteins. In order to study the humoral immune responses against different HCV proteins in patients suffering from chronic HCV infection, we produced three structural (core, E1 and E2) and six nonstructural proteins (NS2, NS3, NS4A, NS4B, NS5A and NS5B) in Sf9 insect cells by using the baculovirus expression system.
Results:
The recombinant HCV core, E1, E2, NS2, NS3, NS4A, NS4B, NS5A and NS5B proteins were purified and used in Western blot analysis to determine antibody responses against individual HCV protein in 68 HCV RNA and antibody positive human sera that were obtained from patients suffering from genotype 1, 2, 3 or 4 infection. These sera were also analysed with INNO-LIA Score test for HCV antibodies against core, NS3, NS4AB and NS5A, and the results were similar to the ones obtained by Western blot method. Based on our Western blot analyses we found that the major immunogenic HCV antigens were the core, NS4B, NS3 and NS5A proteins which were recognized in 97%, 86%, 68% and 53% of patient sera, respectively. There were no major genotype specific differences in antibody responses to individual HCV proteins. A common feature within the studied sera was that all except two sera recognized the core protein in high titers, whereas none of the sera recognized NS2 protein and only three sera (from genotype 3) recognised NS5B.
Conclusions:
The data shows significant variation in the specificity in humoral immunity in chronic HCV patients.</description>
        <link>http://www.virologyj.com/content/6/1/84</link>
                <dc:creator>Maarit Sillanpaa</dc:creator>
                <dc:creator>Krister Melen</dc:creator>
                <dc:creator>Paivi Porkka</dc:creator>
                <dc:creator>Riku Fagerlund</dc:creator>
                <dc:creator>Kaisu Nevalainen</dc:creator>
                <dc:creator>Maija Lappalainen</dc:creator>
                <dc:creator>Ilkka Julkunen</dc:creator>
                <dc:source>Virology Journal 2009, 6:84</dc:source>
        <dc:date>2009-06-23T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1743-422X-6-84</dc:identifier>
        <prism:publicationName>Virology Journal</prism:publicationName>
        <prism:issn>1743-422X</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>84</prism:startingPage>
        <prism:publicationDate>2009-06-23T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.virologyj.com/content/6/1/83">
        <title>Perinatal transmission of human papilomavirus DNA</title>
        <description>The purpose was to study the perinatal transmission of human papillomavirus DNA (HPV-DNA) in 63 mother-newborn pairs, besides looking at the epidemiological factors involved in the viral DNA transmission. The following sampling methods were used: (1) in the pregnant woman, when was recruited, in cervix and clinical lesions of the vagina, vulva and perineal region; (2) in the newborn, (a) buccal, axillary and inguinal regions; (b) nasopharyngeal aspirate, and (c) cord blood; (3) in the children, buccal was repeated in the 4th week and 6th and 12th month of life. HPV-DNA was identified using two methodologies: multiplex PCR (PGMY09 and MY11 primers) and nested-PCR (genotypes 6/11, 16, 18, 31, 33, 42, 52 and 58). Perinatal transmission was considered when concordance was found in type-specific HPV between mother/newborn or mother/child. HPV-DNA genital was detected in 49 pregnant women submitted to delivery. Eleven newborns (22.4%, n=11/49) were HPV-DNA positive. In 8 cases (16.3%, n=8/49) there was type specific HPV concordance between mother/newborn samples. At the end of the first month of life three children (6.1%, n=3/49) became HPV-DNA positive, while two remained positive from birth. In 3 cases (100%, n=3/3) there was type specific HPV concordance between mother/newborn samples. In the 6th month, a child (2%, n=1/49) had become HPV-DNA positive between the 1st and 6th month of life, and there was type specific HPV concordance of mother/newborn samples.  All the HPV-DNA positive children (22.4%, n=11/49) at birth and at the end first month of life (6.1%, n=3/49) became HPV-DNA negative at the age of 6 months. The HPV-DNA positive child (2%, n=1/49) from 1st to the 6th month of life became HPV-DNA negative between the 6th and 12th month of life and one child had anogenital warts. In the twelfth month all (100%, n=49/49) the children studied were HPV-DNA negative. A positive and significant correlation was observed between perinatal transmission of HPV-DNA and the immunodepression of maternal variables (HIV, p=0.007). Finally, the study suggests that perinatal transmission of HPV-DNA occurred in 24.5% (n=12/49) of the cases studied.</description>
        <link>http://www.virologyj.com/content/6/1/83</link>
                <dc:creator>Renato Rombaldi</dc:creator>
                <dc:creator>Eduardo Serafini</dc:creator>
                <dc:creator>Jovana Mandelli</dc:creator>
                <dc:creator>Edineia Zimmermann</dc:creator>
                <dc:creator>Kamille Losquiavo</dc:creator>
                <dc:source>Virology Journal 2009, 6:83</dc:source>
        <dc:date>2009-06-21T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1743-422X-6-83</dc:identifier>
        <prism:publicationName>Virology Journal</prism:publicationName>
        <prism:issn>1743-422X</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>83</prism:startingPage>
        <prism:publicationDate>2009-06-21T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
